2025-10-17 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX), incorporating all the provided data points.

**Report on Recursion Pharmaceuticals Inc. (RXRX)**

Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to discover, develop, and deliver novel medicines.

**1. Performance vs. S&P 500 (VOO)**

*   **RXRX Cumulative Return:** -5.97%
*   **VOO Cumulative Return:** 38.41%
*   **Absolute Divergence:** -55.3%
*   **Relative Divergence:** 6.1%

**Analysis:** RXRX has significantly underperformed the S&P 500 over the period examined.  The negative absolute divergence of -55.3% highlights this.  The relative divergence of 6.1% indicates that RXRX's performance is near the lower end of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2021-2023  | 22.0%  | 81.0% | 26.0%  | -0.2  | 4.7    |
| 2022-2024  | 11.0%  | 81.0% | -10.0% | 0.1   | 3.2    |
| 2023-2025  | 36.0%  | 80.0% | -24.0% | 0.1   | 2.8    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows significant fluctuation year to year, indicating high volatility.
*   **MDD:** High Maximum Drawdown values (around 80%) across all periods suggest substantial risk and potential for large losses.
*   **Alpha:**  Alpha is inconsistent. The negative Alpha in 2022-2024 and 2023-2025 suggests that RXRX underperformed relative to its risk (as measured by Beta) during those periods.
*   **Beta:** Beta values close to 0 indicate a low correlation with the market.
*   **Cap:** Cap values have declined from 4.7B to 2.8B.

**2. Recent Stock Price Movements**

*   **Current Price:** 5.89
*   **Last Market Data:** `{'price': 6.36, 'previousClose': 6.79, 'change': -6.33}`
*   **5-day Moving Average:** 5.64
*   **20-day Moving Average:** 5.18
*   **60-day Moving Average:** 5.25

**Analysis:** The last market data shows a significant negative change of -6.33%, indicating a recent sharp decline. The current price (5.89) is above all of its moving averages (5, 20, 60).

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 63.61
*   **PPO:** 1.38
*   **Hybrid Signal:** Buy 100% of cash (195 shares - Very Safe - MRI:0.90)
*   **Recent Change in Relative Divergence (20 days):** -2.0 (Short-term decline)
*   **Expected Return:** -68.1% (vs. S&P 500, long-term)

**Analysis:**

*   The MRI suggests a medium level of investment recommendation.
*   RSI of 63.61 is approaching overbought territory (typically above 70), indicating potential for a pullback.
*   The PPO is positive, suggesting a potential upward trend but is rather low.
*   The hybrid signal suggests a very safe option, MRI:0.90
*   The negative change in relative divergence suggests a recent downturn.
*   The very negative expected return (-68.1%) raises significant concerns about the long-term outlook.

**4. Recent News & Significant Events**

*   **Positive Catalysts:** Multiple articles highlight potential upside from AI strategy, gains from a major AI event, and whether RXRX can be a "Millionaire Maker."
*   **Mixed Signals:** One article notes RXRX dipping more than the broader market.

**Analysis:** Recent news is a mix of positive and negative sentiment. There's a clear focus on RXRX's AI strategy as a potential growth driver. However, the article mentioning underperformance relative to the market suggests caution.

**4-2. Analyst Opinions**

*   **Consensus:** Hold (Mean of 2.62)
*   **Target Price:** Average $6.47 (High $10.00, Low $3.00)

**Analysis:** Analyst consensus is neutral (Hold). The average target price suggests a potential upside, but the wide range between high and low targets indicates uncertainty. The lack of recent rating changes information makes it difficult to assess the current sentiment.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-08-05 | -0.41 | 0.02 B$   |
| 2025-05-05 | -0.5  | 0.01 B$   |
| 2024-11-06 | -0.34 | 0.03 B$   |
| 2024-08-08 | -0.4  | 0.01 B$   |
| 2025-08-05 | -0.4  | 0.01 B$   |

**Analysis:** RXRX has consistently reported negative EPS. Revenue has fluctuated but remains relatively low. This indicates a lack of profitability.

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.02B    | -5.54%        |
| 2025-03-31 | $0.01B    | -47.31%       |
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%        |
| 2024-06-30 | $0.01B    | 36.14%        |

**Capital and Profitability**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-06-30 | $0.92B    | -18.70%   |
| 2025-03-31 | $0.93B    | -21.68%   |
| 2024-12-31 | $1.03B    | -17.29%   |
| 2024-09-30 | $0.52B    | -18.27%   |
| 2024-06-30 | $0.58B    | -16.69%   |

**Analysis:**

*   **Revenue:** Revenue is inconsistent.
*   **Profit Margin:** Profit margins are generally negative, especially in recent quarters. The exceptions (positive margins in Q3 and Q2 2024) are not sustained.
*   **Equity:** Equity has fluctuated.
*   **ROE:**  ROE is consistently negative, reflecting poor profitability.

**7. Overall Assessment**

Recursion Pharmaceuticals (RXRX) presents a high-risk, high-reward investment opportunity.

*   **Negative Factors:** RXRX has significantly underperformed the S&P 500. It demonstrates negative earnings, inconsistent revenue, negative profit margins, and negative ROE.
*   **Positive Factors:** The company is leveraging AI, which is attracting investor attention.
*   **Neutral Factors:** The average analyst price target suggests some upside, but the range is wide, and the consensus is only a "Hold."

**In conclusion, while the company's focus on AI and recent news coverage provide potential catalysts for growth, the weak financials, negative expected returns, and high volatility suggest a cautious approach is warranted.** Investors should carefully weigh the potential risks and rewards before investing in RXRX. The recent sharp decline in price should also be a cause for concern.
